8-K: NRC Health Reports Steady Revenue, Increased EPS, and CFO Retirement

NRC Health announced its fourth quarter and full year 2023 results, highlighting consistent revenue, increased earnings per share, and the retirement of its CFO.

Summary

• National Research Corporation, also known as NRC Health, reported its financial results for the fourth quarter and full year of 2023.
• The company's revenue remained consistent at $38 million for the fourth quarter of both 2023 and 2022.
• Diluted earnings per share increased to $0.36 in Q4 2023, up from $0.27 in Q4 2022, which included a $0.10 per share foreign currency expense.
• For the full year 2023, the company's return on average equity improved to 51% from 40% in 2022.
• NRC Health returned $55 million to stockholders through dividends and stock repurchases in 2023, with an additional $15 million in stock repurchased in January 2024.
• The company has approximately $30 million of net debt, $30 million available on its revolving line of credit, and $56 million available on its delayed draw term facility as of December 31, 2023.
• The company's CFO, Kevin Karas, will retire effective March 31, 2024, after 13 years of service.
• Linda Stacy, Vice President of Finance, has been promoted to Principal Accounting Officer, effective March 31, 2024.
• A quarterly cash dividend of $0.12 per share was declared, payable on April 15, 2024, to shareholders of record on March 29, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial performance, a record high Net Promoter Score, and a focus on growth and innovation. The CFO's retirement is a transition, but the company has a succession plan in place. The company is returning capital to shareholders and has a strong balance sheet.

Positives

• The company achieved a record high Net Promoter Score of 75, indicating strong customer satisfaction.
• Diluted earnings per share increased for the fourth consecutive quarter.
• The company has a strong capital position with $30 million of net debt and significant available credit.
• The company is focused on growth and innovation initiatives, including AI-enabled solutions.
• The company has a history of returning capital to stockholders through dividends and share repurchases.
• The company is expanding its executive team and product offerings.

Negatives

• Revenue remained flat at $38 million for the fourth quarter of both 2023 and 2022, as increased core sales were offset by reductions in non-core revenue.
• The company is experiencing a reduction in non-core revenue.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's future performance is dependent on the successful rollout of new products and the adoption of AI-enabled solutions.
• The company's ability to increase market share and improve efficiency is subject to various market and operational risks.

Future Outlook

The company expects to roll out new Market Experience, PX, CX, and EX products regularly, and is ramping up resources in sales, IT, and product development, with a focus on AI-enabled solutions. Capital allocation for the remainder of 2024 is expected to focus primarily on growth and innovation initiatives and the regular quarterly dividend.

Management Comments

• Michael Hays, CEO, stated that the company is pleased to start 2024 with momentum from another consecutive quarter of growth in new sales and operating margin.
• Michael Hays, CEO, mentioned the company is better positioned than ever with industry-leading solutions and a record high Net Promoter Score of 75.
• Michael Hays, CEO, expressed excitement about the expanded executive team and growth plan.
• Kevin Karas, CFO, noted that diluted earnings per share increased for the fourth straight quarter through a combination of sequentially improving new sales, focused cost control, and lower share count.
• Michael Hays, CEO, acknowledged Kevin Karas's leadership and contributions over 13 years, highlighting the doubling of revenue and quadrupling of market capitalization during his tenure.

Industry Context

This announcement reflects a focus on customer experience and technological innovation, which are key trends in the healthcare industry. The company's emphasis on AI-enabled solutions aligns with the broader industry shift towards leveraging technology to improve efficiency and patient outcomes. The focus on returning capital to shareholders is also a common practice in the industry.

Comparison to Industry Standards

• The company's Net Promoter Score of 75 is exceptionally high, indicating a strong competitive position in customer satisfaction compared to other healthcare service providers.
• The company's return on average equity of 51% is a strong result, suggesting efficient use of shareholder capital compared to industry averages.
• The company's focus on AI-enabled solutions is in line with the industry trend of adopting advanced technologies to improve service delivery and efficiency, similar to companies like Medidata Solutions and Veeva Systems.
• The company's capital allocation strategy, which includes dividends and share repurchases, is a common practice among mature healthcare companies, similar to companies like Cardinal Health and McKesson.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased earnings per share, dividends, and stock repurchases.
• Employees may see new opportunities with the company's growth and innovation initiatives.
• Customers will benefit from the company's focus on improving the patient experience and new product offerings.
• The company's strong financial position and focus on growth should benefit suppliers and creditors.

Next Steps

• The company will roll out new Market Experience, PX, CX, and EX products.
• The company will continue to ramp up resources in sales, IT, and product development.
• The company will focus on AI-enabled solutions.
• The company will hold a conference call on February 14, 2024, to discuss the results.
• The company will pay a quarterly cash dividend on April 15, 2024.

Key Dates

Keywords

financial results, earnings per share, revenue, dividends, stock repurchases, CFO retirement, Net Promoter Score, capital allocation, healthcare, AI